>>>welcome visitor, haven't logged in. Login
Subscribe Now Contact us  
Font Size:  A A A Search “Fabao” Window English 中文 = 简体  繁体
  Favorite   DownLoad   Print
 
No. 4 of Trial of Five Typical Cases on Food and Pharmaceutical Product Dispute Issued by the Supreme People's Court: Cong Lisong v. Beijing Panjiayuan Clinic of Ciming Checkup Management Group Co., Ltd. (Dispute over product vendor liability)
最高人民法院公布五起审理食品药品纠纷典型案例之四:丛李松诉慈铭健康体检管理集团股份有限公司北京潘家园门诊部产品销售者责任纠纷案
【法宝引证码】

No. 4 of Trial of Five Typical Cases on Food and Pharmaceutical Product Dispute Issued by the Supreme People's Court: Cong Lisong v. Beijing Panjiayuan Clinic of Ciming Checkup Management Group Co., Ltd. (Dispute over product vendor liability)
(Dispute over product vendor liability)
最高人民法院公布五起审理食品药品纠纷典型案例之四:丛李松诉慈铭健康体检管理集团股份有限公司北京潘家园门诊部产品销售者责任纠纷案
[核心术语]
虚假广告;欺诈;加倍赔偿
[争议焦点]
1.经营者利用虚假广告销售药品,给消费者造成损害的,消费者是否有权要求经营者加倍赔偿?
[案例要旨]
消费者因经营者利用虚假广告提供商品或者服务其合法权益受到损害的可以向经营者要求赔偿。根据2013年修订前的《消费者权益保护法》第四十九条的规定“经营者提供商品或者服务有欺诈行为的应当按照消费者的要求增加赔偿其受到的损失...
No. 4 of Trial of Five Typical Cases on Food and Pharmaceutical Product Dispute Issued by the Supreme People's Court: Cong Lisong v. Beijing Panjiayuan Clinic of Ciming Checkup Management Group Co., Ltd. (Dispute over product vendor liability) 最高人民法院公布五起审理食品药品纠纷典型案例之四:丛李松诉慈铭健康体检管理集团股份有限公司北京潘家园门诊部产品销售者责任纠纷案
1. Basic Facts (一)基本案情
Plaintiff Cong Lisong read an advertisement of “Shenlin Oral Liquid” with the title of “New Breakthrough in the Treatment of Advanced Tumor” on The Mirror issued on June 2, 2012. It was said in the advertisement that the absorption and utilization rate of this medicine could be several times or above of that of traditional Chinese medicine; and the address of the specialty store below the advertisement was 100 meters north of the west gate of Cancer Hospital of Chinese Academy of Medical Sciences, Zuo'anmen Bridge, 2nd East Ring, Beijing Municipality (Ciming Traditional Chinese with Western Medicine Clinic). In order to treat his aunt who was suffering from a cancer, on the same day, Cong Licong purchased one piece of “Shenlin Oral Liquid (Xiao'aiping Oral Liquid)” at the price of 450 yuan from Beijing Panjiayuan Clinic of Ciming Checkup Management Group Co., Ltd. (hereinafter referred to as the “Panjiayuan Clinic”), on whose package there were characters of “Approved by the State Z20050778.” He afterwards found that this medicine was a prescription drug that must be used under the guidance of a physician and the Panjiayuan Clinic did not give him any instruction in the sale of such medicine. According to the Announcement on Illegal Advertisements of Pharmaceutical Products issued by the Beijing Drug Administration in March 2012, “2. Illegal advertisements involve 33 varieties of pharmaceutical products and there are acts of issuing advertisements without examination and falsifying the authorized advertisement content without approval. Whereby, two pharmaceutical products named “Jieshitong Tea” and “Shenlin Oral Liquid” had serious circumstances of issuing illegal advertisements. It was alleged in the advertisement of the pharmaceutical product named “Shenlin Oral Liquid” that it was prepared by using the “therapy of atomic trace breaking nucleus” and it contained “microtubule repression elements” and “specific activator factors,” which may kill and eliminate tumor cells and prevent the reoccurrence, spread, and metastasis of tumor. The advertisements of the above pharmaceutical products contained content that exaggerated the indications of such pharmaceutical products and unscientifically indicated their efficiency, which have seriously misled and cheated consumers.” In the Summary Sheet for Illegal Advertisements of Pharmaceutical Products annexed to the Announcement of Illegal Advertisements of Pharmaceutical Products issued by the Beijing Drug Administration during the period from April to June 2012, “Shenlin Oral Liquid” was included and the operating enterprise indicated included “Ciming Traditional Chinese with Western Medicine Clinic.” Cong Lisong maintained that the Panjiayuan Clinic exaggerated the indications and efficiency of the pharmaceutical product in advertising, which seriously misled and cheated consumers. Therefore, he filed a lawsuit in the People's Court of Chaoyang District, Beijing Municipality, requiring the Panjiayuan Clinic to refund 450 yuan and pay damages of 450 yuan, work delay expenses of 9,099 yuan, and mental damage compensation of 1 yuan. 原告丛李松从2012年6月2日《法制晚报》上看到题为“晚期肿瘤治疗新突破”的“神麒口服液”广告,该广告称这种药物的吸收利用率可达传统中药的几倍以上;该广告下方显示专卖地址为东二环左安门桥肿瘤医院西门北走100米【慈铭中西医门诊药房】。为给其患有癌症的婶婶治病,丛李松当日在慈铭健康体检管理集团股份有限公司北京潘家园门诊部(以下简称潘家园门诊部)购买了1盒售价450元的“神麒口服液(消癌平口服液)”,上面标有“国家药准字Z20050778”字样。后发现该药品是必须在医师指导下使用的处方药,而在销售时也没有进行指导说明。北京市药品监督管理局于2012年3月发布的《违法药品广告公告》中写有:“二、违规广告涉及药品品种33个,存在未经审查发布和擅自篡改广告审批内容的行为。其中标示名称为‘结石通茶'、‘神麒口服液'两种药品发布违规广告情节严重。标示名称为‘神麒口服液'的药品在广告宣称采用‘原子微量破核疗法'研制,含‘微管阻遏素'和‘特异激活因子',可杀死清除肿瘤细胞,防止肿瘤的复发扩散转移。以上药品的广告宣传含夸大药品适应症、有不科学地表示功效的保证等内容,严重误导和欺骗消费者。”北京市药品监督管理局于2012年4月至6月期间发布的《违法药品广告公告》所附的《违规药品广告情况汇总表》中均包括“神麒口服液”,其后标示的经营企业均包括“慈铭中西医门诊药房”。丛李松认为潘家园门诊部在广告中夸大药品的适应症和功效,严重误导和欺骗消费者,故向北京市朝阳区人民法院起诉,要求其退还货款450元,赔偿450元,支付误时费9099元,赔偿精神损失费1元。
...... ......

Dear visitor, as a premium member of this database, you will get complete access to all content.Please go premium and get more.

1. To become a premium member, please call 400-810-8266 Ext. 171.

2. Binding to the account with access to this database.

3. Apply for a trial account.

4. To get instant access to a document, you can Pay Amount 【¥200.00】 for your single purchase.
 
您好:您现在要进入的是北大法宝英文库会员专区。
如您是我们英文用户可直接 登录,进入会员专区查询您所需要的信息;如您还不是我们 的英文用户;您可通过网上支付进行单篇购买,支付成功后即可立即查看本篇内容。
Tel: +86 (10) 82689699, +86 (10) 82668266 ext. 153
Mobile: +86 13311570713
Fax: +86 (10) 82668268
E-mail:info@chinalawinfo.com
     
     
Scan QR Code and Read on Mobile
【法宝引证码】        北大法宝en.pkulaw.cn
Message: Please kindly comment on the present translation.
 
Confirmation Code:
Click image to reset code
 
  Translations are by lawinfochina.com, and we retain exclusive copyright over content found on our website except for content we publish as authorized by respective copyright owners or content that is publicly available from government sources.

Due to differences in language, legal systems, and culture, English translations of Chinese law are for reference purposes only. Please use the official Chinese-language versions as the final authority. Lawinfochina.com and its staff will not be directly or indirectly liable for use of materials found on this website.

We welcome your comments and suggestions, which assist us in continuing to improve the quality of our materials as we dynamically expand content.
 
Home | About us | Disclaimer | Chinese